JAK2 and COVID-19: Fedratinib is a highly selective inhibitor of JAK2 and a modest inhibitor of JAK1 and JAK3 [93] showed efficacy against cytokine storms caused by COVID-19 via the downregulation of T helper-17-associated cytokines [68].